Skip to main content
S&P 5007,765.36-0.47%DOW51,231.64+0.10%NASDAQ27,193.34-1.25%BTC$82,437.00+0.02%ETH$2,488.81-1.91%GOLD$4,203.90+1.13%OIL$90.51-1.07%
Smart Investors Daily
SID Premium
LI

NASDAQ · LIMN

Liminatus Pharma, Inc. Class A Common Stock

Healthcare · Biotechnology

$3.69

Down-$0.19 (-4.90%)

Updated Oct 9, 2026, 11:15 AM

SID Score

5.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
23.41M
P/E ratio
-9.06
Dividend yield
0.00%
52-week range
$0.10 – $7.48
Volume
38.56K
Avg. volume
630.53K

Price performance · LIMN

LIMN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 8, 2026

LIMN closed at $3.69 after 21 trading sessions, up 1.65% for the selected period.

Last close
$3.69
Period change
+1.65%
Period low
$3.33
Period high
$4.27
Daily close
View OHLC price history
LIMN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 8, 2026$3.95$3.95$3.5308$3.6938.56K
Oct 7, 2026$3.7006$3.89$3.65$3.8822.94K
Oct 6, 2026$3.95$3.95$3.69$3.7012.63K
Oct 5, 2026$3.80$4.08$3.80$3.9918.09K
Oct 2, 2026$3.75$3.95$3.75$3.9024.33K
Oct 1, 2026$3.74$3.86$3.65$3.7528.17K
Sep 30, 2026$3.81$3.9738$3.7101$3.739.26K
Sep 29, 2026$4.23$4.3099$3.83$3.9138.36K
Sep 28, 2026$4.14$4.4794$4.1302$4.2718.55K
Sep 25, 2026$4.26$4.34$4.0906$4.19518.58K
Sep 24, 2026$4.16$4.23$4.00$4.1816.97K
Sep 23, 2026$4.05$4.1369$3.90$4.0317.7K
Sep 22, 2026$3.71$4.26$3.6406$4.0788.5K
Sep 21, 2026$3.68$3.72$3.56$3.6416.14K
Sep 18, 2026$3.43$3.675$3.41$3.4823.26K
Sep 17, 2026$3.35$3.44$3.3452$3.398.87K
Sep 16, 2026$3.46$3.545$3.32$3.3315.7K
Sep 15, 2026$3.50$3.58$3.4147$3.5114.26K
Sep 14, 2026$3.45$3.615$3.29$3.5238.01K
Sep 11, 2026$3.63$3.675$3.46$3.4731.46K
Sep 10, 2026$3.54$3.80$3.4505$3.6320.18K

Latest LIMN news

The latest Smart Investors Daily articles mentioning LIMN.

Stock researchCompany · Overview

LIMN research

Overview

Company profile and research snapshot.

Company profile

Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule

FULLERTON, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid price rule. As previously disclosed, on January 15, 2026 the Company received a notice from Nasdaq indicating that the closing bid price of the Company’s common stock had been below $1.00 for 30 consecutive business days, and, consequently, the Company was not in compliance with Nasdaq Listing

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By